Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate and other antibacterial drugs, erythromycin ethylsuccinate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin ethylsuccinate for oral suspension usp is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes, streptococcus pneumoniae, or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the e

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

par pharmaceutical, inc. - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate for oral suspension and other antibacterial drugs,  erythromycin ethylsuccinate for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin ethylsuccinate for oral suspension is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes , streptococcus pneumoniae , or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. inf

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

cadila pharmaceuticals limited - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate for oral suspension and other antibacterial drugs, erythromycin ethylsuccinate for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin ethylsuccinate for oral suspension is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes, streptococcus pneumoniae , or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. inf

Australia - engleză - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - erythromycin lactobionate, quantity: 1.4882 g (equivalent: erythromycin, qty g) - injection, powder for - excipient ingredients: nitrogen - oral erythromycin is not considered to be the antibiotic of choice in severely ill patients. erythromycin sterile powder for injection (sterile erythromycin lactobionate) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. intravenous therapy should be replaced by oral administration at the appropriate time. upper respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae); haemophilus influenzae (many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). lower respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae). respiratory tract infections due to mycoplasma pneumoniae. skin and skin structure infections caused by streptococcus pyogenes and staphylococcus aureus (resistant staphylococci may emerge during treatment). diphtheria - as an adjunct to diphtheria antitoxin in infections due to corynebacterium diphtheriae to prevent establishment of carriers and to eradicate the organism in carriers. acute pelvic inflammatory disease caused by neisseria gonorrhoeae: erythromycin powder for injection (sterile erythromycin lactobionate) followed by erythromycin stearate, base or ethyl succinate orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by n. gonorrhoeae in female patients with a history of sensitivity to penicillin. before treatment of gonorrhoea, patients who are suspected of also having syphilis should have microscopic examination for t. pallidum (by immunofluorescence or darkfield) before receiving erythromycin and monthly serologic tests for a minimum of 4 months thereafter. legionnaires' disease caused by legionella pneumophila. although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires' disease.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

physicians total care, inc. - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d), sulfisoxazole acetyl (unii: wbt5qh3ked) (sulfisoxazole - unii:740t4c525w) - erythromycin ethylsuccinate 200 mg in 5 ml - for treatment of acute otitis media in children that is caused by susceptible strains of haemophilus influenzae . erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension is contraindicated in the following patient populations: use in pregnant women at term, in children less than 2 months of age, and in mothers nursing infants less than 2 months of age is contraindicated because sulfonamides may promote kernicterus in the newborn by displacing bilirubin from plasma proteins. erythromycin is contraindicated in patients taking terfenadine. (see precautions, drug interactions:.)

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

rebel distributors corp - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d), sulfisoxazole acetyl (unii: wbt5qh3ked) (sulfisoxazole - unii:740t4c525w) - erythromycin ethylsuccinate 200 mg in 5 ml - for treatment of acute otitis media in children that is caused by susceptible strains of haemophilus influenzae . erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension is contraindicated in the following patient populations: use in pregnant women at term, in children less than 2 months of age, and in mothers nursing infants less than 2 months of age is contraindicated because sulfonamides may promote kernicterus in the newborn by displacing bilirubin from plasma proteins. erythromycin is contraindicated in patients taking terfenadine. (see precautions, drug interactions:.)

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

mayne pharma inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - erythromycin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes, streptococcus pneumoniae, or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved) (see appropriate sulfonamide labeling for prescribing information). lower respiratory tract infections of mild to moderate severity caused by streptococcus pneumoniae or streptococcus pyogenes. listeriosis caused by listeria monocytogenes. pertussis (whooping cough) caused by bordetella pertussis. erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible indivi

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

direct rx - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 5 mg in 1 g - for the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. for prophylaxis of ophthalmia neonatorum due to n. gonorrhoeae or c. trachomatis. the effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing n. gonorrhoeae is not established. for infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin g should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. topical prophylaxis alone is inadequate for these infants. this drug is contraindicated in patients with a history of hypersensitivity to erythromycin.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

h.j. harkins company, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 5 mg in 1 g - for the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. for prophylaxis of ophthalmia neonatorum due to n. gonorrhoeae or c. trachomatis . the effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing n. gonorrhoeae is not established. for infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin g should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. topical prophylaxis alone is inadequate for these infants. this drug is contraindicated in patients with a history of hypersensitivity to erythromycin.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

physicians total care, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 20 mg - erythromycin pledgets, usp are indicated for the topical treatment of acne vulgaris. erythromycin pledgets, usp are contraindicated in those individuals who have shown hypersensitivity to any of its components.